Asunto(s)
COVID-19 , Pandemias , Europa (Continente)/epidemiología , Humanos , Pandemias/prevención & control , SARS-CoV-2RESUMEN
The Innovative Medicines Initiative is a public-private partnership between the European Union and the pharmaceuticals industry that was established in 2008, with an overall budget of 5.3 billion from 2008 until 2024. The objective of the initiative is to boost pharmaceutical innovation in Europe and speed up the development of innovative medicines, vaccines and medical technologies, in particular in areas with high unmet needs. This article discusses the objectives of the initiative, its governance and main results and impact. The initiative has proved to be a unique platform for multi-stakeholder collaborations across Europe. It has contributed to the acceleration of the development process for medicines, from drug discovery to clinical development. The initiative has made important steps towards accessing and using real-world evidence for pharmaceutical research and development, and for healthcare decision-making. Several projects have contributed to a better understanding of the causes of diseases, and some are already delivering results, such as a vaccine against Ebola virus. The initiative has also significantly contributed to building capacity and resources for open use by the broader research and innovation community.
Asunto(s)
Cooperación Internacional , Colaboración Intersectorial , Participación del Paciente/tendencias , Enfermedades Raras/diagnóstico , Investigación Biomédica Traslacional/tendencias , Acceso a la Información , Objetivos , Accesibilidad a los Servicios de Salud/organización & administración , Accesibilidad a los Servicios de Salud/tendencias , Historia del Siglo XXI , Humanos , Difusión de la Información , Prevalencia , Enfermedades Raras/epidemiología , Enfermedades Raras/etiología , Enfermedades Raras/terapia , Sistema de Registros , Investigación Biomédica Traslacional/economía , Investigación Biomédica Traslacional/historia , Investigación Biomédica Traslacional/organización & administraciónRESUMEN
Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment and care. It helps to address the challenge of the aging of the population, an increase in chronic disease and increasing healthcare costs. The EU is developing policies to move toward PM. This is underpinned by a sustained and significant investment starting in 2010. So far, a total of 3.2 billion has been invested in PM research across the medical innovation cycle 'from bench to bedside'. This investment has come from the research framework programs FP7 and Horizon 2020. About a third of the total investment has been made in the context of the Innovative Medicines Initiative, the largest public-private partnership in life sciences globally.